Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma

L Castagna, S Bramanti, R Devillier, B Sarina, R Crocchiolo, S Furst, J El-Cheikh, A Granata, C Faucher, S Harbi, L Morabito, J Mariotti, S Puvinathan, P J Weiller, C Chabannon, D Mokart, C Carlo-Stella, R Bouabdallah, A Santoro, D Blaise

Research output: Contribution to journalArticle

Abstract

We investigated the use of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of advanced Hodgkin lymphoma (HL). Sixty-two consecutive HL patients underwent haplo-HSCT. Unmanipulated stem cells and post-transplant cyclophosphamide were given to all patients as GVHD prophylaxis. At 100 days, the cumulative incidence of grades 2-3 and grades 3-4 acute GVHD was 23% and 4%, respectively. The chronic GVHD (cGVHD) cumulative incidence was 16%, with one patient experiencing severe cGVHD. The 3-year OS, PFS, relapse rates and 1-year non-relapse mortality (NRM) were 63%, 59%, 21% and 20%, respectively. Uncontrolled disease status and high hematopoietic cell transplantation comorbidity index (HCT-CI) were associated with lower OS, whereas PBSC was an independent protective factor. Uncontrolled disease and HCT-CI >2 was predictive for NRM. Finally, disease status other than CR was predictive of relapse. In conclusion, haplo-HSCT is a valid treatment in advanced HL, offering excellent rates of survival and acceptable toxicities.

Original languageEnglish
Pages (from-to)683-688
Number of pages6
JournalBone Marrow Transplantation
Volume52
Issue number5
DOIs
Publication statusPublished - May 2017

    Fingerprint

Keywords

  • Journal Article

Cite this

Castagna, L., Bramanti, S., Devillier, R., Sarina, B., Crocchiolo, R., Furst, S., El-Cheikh, J., Granata, A., Faucher, C., Harbi, S., Morabito, L., Mariotti, J., Puvinathan, S., Weiller, P. J., Chabannon, C., Mokart, D., Carlo-Stella, C., Bouabdallah, R., Santoro, A., & Blaise, D. (2017). Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplantation, 52(5), 683-688. https://doi.org/10.1038/bmt.2016.348